CLIDANAC

Possibly Marketed Outside US

Details

Stereochemistry	RACEMIC
Molecular Formula	C16H19ClO2
Molecular Weight	278.774
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

SMILES

OC(=O)C1CCC2=CC(C3CCCCC3)=C(Cl)C=C12

InChI

InChIKey=OIRAEJWYWSAQNG-UHFFFAOYSA-N

InChI=1S/C16H19ClO2/c17-15-9-13-11(6-7-12(13)16(18)19)8-14(15)10-4-2-1-3-5-10/h8-10,12H,1-7H2,(H,18,19)

HIDE SMILES / InChI

Description

Clidanac is an anti-inflammatory agent developed in Japan for the treatment of rheumatoid arthritis. The drug is mixture of two isomers, d- and l-, and the d-form is more active than the l-form. Therapeutic effect of clidanac is mediated by the inhibition of prostaglandin biosynthesis.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Prostaglandin E synthase 2 2	Inhibitor 8,504		2.7 µM [IC50]
Prostamide/prostaglandin F synthase 1	Inhibitor 8,504		2.9 µM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Rheumatoid arthritis 320	Palliative		Phase II 1,147	Unknown

PubMed

Show entries

Title	Date	PubMed
6-chloro-5-cyclohexylindan-1-carboxylic acid (TAI-284), a new antiinflammatory agent.	1971 Mar	5553051
Anti-inflammatory, analgesic and antipyretic activities of 6-chloro-5-cyclohexylindan-1-carboxylic acid (TAI-284).	1971 Oct	4401197
Metabolism of 6-chloro-5-cyclohexylindane-1-carboxylic acid (TAI-284), a new non-steroidal anti-inflammatory agent. I. Absorption, distribution and excretion in rats.	1973 Oct	4774631
Inhibition of prostaglandin biosynthesis by clidanac and related compounds: structural and conformational requirements for PG synthetase inhibition.	1981 Jan	6114148
[Influence of indomethacin and clidanac on the blood pressure lowering effect of beta-blockers].	1983 Jan	6133820

Showing 1 to 5 of 6 entries

Previous1 2Next

Patents

Sample Use Guides

In Vivo Use Guide

Unknown

Route of Administration: Unknown

In Vitro Use Guide

Inhibitory effect of clidanac on ADP-induced rat platelet aggregation was tested in vitro. At concentrations 1*10(-3), 5*10(-4), 1*10(-4) M the drug produced 76, 16 and 0% of inhibition. At 10(-4) M the drug caused 61% of inhibition of the heat-induced erythrocyte lysis.

Show entries

Name

Type

Language

BRITAI

Preferred Name

English

CLIDANAC

Official Name

English

(±)-CLIDANAC

Common Name

English

(±)-TAI-284

Common Name

English

clidanac [INN]

Common Name

English

Showing 1 to 5 of 13 entries

Previous1 2 3Next

Show entries

Classification Tree

Code System

Code

Analgesic and Antipyretic

NCI_THESAURUS

C257

Showing 1 to 1 of 1 entries

Previous1Next

Show entries

Code System

Code

Type

Description

MESH

C059095

PRIMARY

PUBCHEM

120108

PRIMARY

CAS

28968-07-2

SUPERSEDED

NCI_THESAURUS

C77342

PRIMARY

MERCK INDEX

m654

PRIMARY

Merck Index

Showing 1 to 5 of 13 entries

Previous1 2 3Next

ACTIVE MOIETY


					UA6HM01WAK

CLIDANAC